Historie von Umsatz, Gewinn und Cashflow aus den offiziellen Geschäftsberichten.
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals.
Interaktive Charts und vollständige Abschlüsse ansehen → Bewertungsmodell (DCF) →
| Gewinn- und Verlustrechnung | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gesamtumsatz | $11.5B | $11.2B | $10.6B | $10.4B | $10.1B | $12.1B | $11.7B | $11.4B | $11.1B | $10.6B | $10.2B | $10.0B | $10.7B | $9.4B | $13.9B | $13.9B | $12.8B | $12.6B | $12.3B | $11.3B | $10.4B |
| Bruttoergebnis | $3.5B | $3.4B | $4.0B | $4.2B | $3.5B | $4.7B | $4.6B | $4.8B | $4.8B | $4.5B | $4.1B | $4.1B | $4.6B | $4.2B | $7.1B | $7.0B | $6.0B | $6.5B | $6.1B | $5.5B | $4.7B |
| Bruttomarge % | 30.1% | 30.0% | 37.5% | 40.1% | 35.3% | 38.9% | 39.3% | 41.9% | 42.9% | 42.3% | 40.5% | 41.6% | 42.7% | 44.2% | 51.2% | 50.7% | 46.4% | 51.9% | 49.6% | 49.0% | 45.6% |
| Betriebsergebnis (EBIT) | ($274M) | ($308M) | $14M | $707M | ($2.8B) | $1.4B | $1.6B | $1.8B | $1.6B | $1.3B | $745M | $449M | $656M | $496M | $2.8B | $2.9B | $2.1B | $2.9B | $2.6B | $2.2B | $1.8B |
| Operative Marge % | -2.4% | -2.7% | 0.1% | 6.8% | -28.3% | 11.1% | 13.8% | 15.6% | 14.3% | 12.2% | 7.3% | 4.5% | 6.1% | 5.3% | 20.2% | 21.2% | 16.6% | 22.9% | 20.8% | 19.2% | 17.7% |
| Jahresüberschuss | ($1.1B) | ($957M) | ($649M) | $2.7B | ($2.4B) | $1.3B | $1.1B | $1.0B | $1.5B | $602M | $5.0B | $968M | $2.5B | $2.0B | $2.3B | $2.2B | $1.4B | $2.2B | $2.0B | $1.7B | $1.4B |
| Nettomarge % | -9.3% | -8.5% | -6.1% | 25.6% | -24.2% | 10.6% | 9.4% | 8.8% | 13.9% | 5.7% | 48.9% | 9.7% | 23.3% | 21.4% | 16.7% | 16.0% | 11.1% | 17.5% | 16.3% | 15.2% | 13.5% |
| EBITDA | — | $766M | $1.1B | $1.7B | ($1.8B) | $2.2B | $2.3B | $1.9B | $2.5B | $1.9B | $5.8B | $1.3B | $1.4B | $1.2B | $3.7B | $3.6B | $2.7B | $3.5B | $3.2B | $2.8B | $2.4B |
| Ergebnis je Aktie (EPS) | $-2.07 | $-1.87 | $-1.27 | $5.25 | $-4.83 | $2.53 | $2.13 | $1.93 | $2.83 | $1.08 | $9.01 | $1.76 | $4.56 | $3.66 | $4.18 | $3.88 | $2.39 | $3.59 | $3.16 | $2.61 | $2.13 |
| Ausstehende Aktien (Mio.) | — | 513M | 510M | 506M | 504M | 508M | 517M | 519M | 546M | 555M | 551M | 549M | 547M | 549M | 556M | 573M | 594M | 614M | 637M | 654M | 656M |
Quelle: veröffentlichte Unternehmensberichte (SEC). Bitte prüfen Sie die Zahlen vor Verwendung auf SEC EDGAR.
Bilanzen, Cashflow-Rechnungen, Quartalsdaten und alle Kennzahlen finden Sie im interaktiven Viewer für BAX. /companies/us/BAX
Die Informationen auf dieser Website dienen ausschließlich Bildungs- und Informationszwecken und stellen keine Anlageberatung dar. Es werden keine Kursziele und keine Anlageurteile veröffentlicht.
About TickerBase · Data methodology & sources · Privacy · Terms